To include your compound in the COVID-19 Resource Center, submit it here.

BioMimetic falls as FDA questions Augment

BioMimetic Therapeutics Inc. (NASDAQ:BMTI) fell $4.73 (35%) to $8.66 on

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE